What Is End-of-Life Care Like for Advanced Pancreatic Neuroendocrine Tumor (pNET)?
By CRYSTAL BAI •
The short answer: Pancreatic neuroendocrine tumors (pNETs) are rare tumors of the pancreas with much better prognosis than pancreatic adenocarcinoma. When advanced or treatment-resistant, pNETs cause hormone-related symptoms (insulin excess, gastrin excess, etc.) alongside liver metastasis symptoms. Palliative care manages hormonal syndromes, hepatic disease, and symptom burden to preserve quality of life.
Understanding Advanced pNETs
Pancreatic neuroendocrine tumors (pNETs) are distinct from common pancreatic adenocarcinoma — they arise from endocrine cells in the pancreas and have dramatically different biology, treatment options, and prognosis. pNETs range from indolent grade 1 tumors that may be stable for years, to grade 3 tumors that are aggressive.
pNETs may be functional (secreting hormones causing distinct syndromes) or non-functional:
- Insulinoma: Secretes insulin; hypoglycemia episodes
- Gastrinoma (Zollinger-Ellison syndrome): Secretes gastrin; severe peptic ulcers
- VIPoma: Secretes VIP; watery diarrhea, hypokalemia
- Glucagonoma: Secretes glucagon; skin rash (necrolytic migratory erythema), diabetes
- Non-functional pNET: No hormone syndrome; most common; presents with mass symptoms
Symptoms in Advanced pNET
- Hepatic metastases: Liver-dominant spread causes pain, fatigue, jaundice as disease progresses
- Hormonal syndromes: Continued or worsened functional syndromes in metastatic disease — controlling insulin levels, gastrin, or VIP in metastatic disease requires ongoing attention
- Abdominal pain: From liver capsule distension, primary tumor, or mesenteric involvement
- Carcinoid-like symptoms: Some pNETs (particularly those with liver metastases) develop carcinoid syndrome — flushing, diarrhea, wheezing
- Fatigue and weight loss: Common in advanced disease
Palliative Care for pNET
- Somatostatin analogues (octreotide/lanreotide): Continue even in palliative setting — control functional syndromes, slow tumor growth, improve quality of life
- Liver-directed therapy: TACE (transarterial chemoembolization) or ablation for hepatic-dominant disease can provide months of symptomatic relief
- Peptide receptor radionuclide therapy (PRRT): Lutetium-177 DOTATATE (Lutathera) is a key treatment for SSTR-positive pNETs that improves survival and symptoms — discuss timing with NET specialist
- Hypoglycemia management: Ongoing insulin excess requires glucose support, diazoxide, or octreotide
- Pain management: Hepatic and abdominal pain management
pNET Community and Specialist Resources
Given pNETs' distinct biology, management at a specialized neuroendocrine tumor center is strongly recommended. The North American Neuroendocrine Tumor Society (NANETS) and European Neuroendocrine Tumor Society (ENETS) maintain treatment guidelines and specialist directories. The Carcinoid Cancer Foundation and NET Research Foundation provide patient support.
Frequently Asked Questions
Is pancreatic NET the same as pancreatic cancer?
No — pancreatic neuroendocrine tumors (pNETs) are very different from pancreatic adenocarcinoma (the most common pancreatic cancer). pNETs arise from endocrine cells, grow more slowly in most cases, respond to different treatments, and have a much better prognosis. The two-year survival for early pNET is over 90%, compared to roughly 10% for pancreatic adenocarcinoma. This distinction is critically important.
What is PRRT therapy for pNETs?
Peptide receptor radionuclide therapy (PRRT) — specifically lutetium-177 DOTATATE (Lutathera) — uses a radioactive molecule that targets somatostatin receptors expressed on NET cells. It delivers targeted radiation to tumor cells. The NETTER-1 trial showed significant progression-free survival benefit. PRRT requires SSTR-positive tumors on imaging and is typically administered at specialized nuclear medicine centers.
How are functional pNET syndromes managed palliatively?
Somatostatin analogues (octreotide LAR, lanreotide) are continued in palliative and late-stage pNET to control functional syndromes. For insulinoma: diazoxide, octreotide, glucagon, and continuous IV glucose. For VIPoma: octreotide, fluid/electrolyte replacement. For gastrinoma: PPIs (high-dose), octreotide. These symptom-directed therapies remain important throughout the disease course.
When should a pNET patient enroll in hospice?
Hospice becomes appropriate when disease-directed treatment is no longer providing meaningful benefit and prognosis is estimated at 6 months or less. This is often later in pNET than other cancers, given the longer disease course. Many pNET patients continue somatostatin analogues through hospice for symptom control — this is appropriate and not inconsistent with comfort-focused care.
What is the role of a multidisciplinary tumor board for pNET?
pNETs require multidisciplinary management — surgery, medical oncology, interventional radiology, nuclear medicine (for PRRT), gastroenterology, and palliative care. Decisions about treatment sequencing (when to use PRRT vs. chemotherapy vs. mTOR inhibitors vs. liver-directed therapy) are complex and benefit from expert team discussion. NET specialist centers routinely use tumor boards for these decisions.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.